The United States Patent and Trademark Office has found that Hovione’s method for making flumethasone and an analogue was not obvious, upholding the company’s patent. A previous reexamination based on a 2005 claim had found that the method was obvious and that the patent should be canceled. An appeals board overturned that ruling after hearing oral arguments in September. Read the company’s press release.
Hovione wins patent case involving fluticasone intermediates
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA
